ArticleLeukemia2017

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.

J Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.